PCVX

Vaxcyte
D

PCVX

60.350
USD
-2.46
(-3.92%)
مغلق
آخر تحديث: · متأخرة 15 دقيقة
حجم التداول
54,755
الربح لكل سهم
-4
العائد الربحي
-
P/E
-8
حجم السوق
9,498,465,559

العنوان: Vaxcyte

القطاع: الرعاية الصحية
الصناعة: Biotechnology
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.